

# **SUPPLEMENTARY SLIDES**

**Q1 2022**

For the period ended March 26, 2022

**Loblaw**  
Companies  
Limited

# FORWARD LOOKING STATEMENTS

This presentation for Loblaw Companies Limited (“Loblaw” or “the Company”) contains forward-looking statements about the Company’s objectives, plans, goals, aspirations, strategies, financial condition, results of operations, cash flows, performance, prospects, opportunities and legal and regulatory matters. Specific forward-looking statements in this presentation include, but are not limited to, statements with respect to the Company’s anticipated future results, events and plans, strategic initiatives and restructuring, regulatory changes including further healthcare reform, future liquidity, planned capital investments, and the status and impact of information technology systems implementations. Forward-looking statements are typically identified by words such as “expect”, “anticipate”, “believe”, “foresee”, “could”, “estimate”, “goal”, “intend”, “plan”, “seek”, “strive”, “will”, “may” and “should” and similar expressions, as they relate to the Company and its management.

Forward-looking statements reflect the Company’s estimates, beliefs and assumptions, which are based on management’s perception of historical trends, current conditions and expected future developments, as well as other factors it believes are appropriate in the circumstances. The Company’s expectation of operating and financial performance in 2022 is based on certain assumptions including assumptions about the COVID-19 pandemic, environmental and social risks (including climate change), healthcare reform impacts, inflation, anticipated cost savings and operating efficiencies and anticipated benefits from strategic initiatives. The Company’s estimates, beliefs and assumptions are inherently subject to significant business, economic, competitive and other uncertainties and contingencies regarding future events and as such, are subject to change. The Company can give no assurance that such estimates, beliefs and assumptions will prove to be correct.

Numerous risks and uncertainties could cause the Company’s actual results to differ materially from those expressed, implied or projected in the forward-looking statements, including those described in Section 9 “Enterprise Risks and Risk Management” of the Company’s MD&A for the 52 weeks ended January 1, 2022, and the Company’s Annual Information Form (“AIF”) (for the year ended January 1, 2022).

Other risks and uncertainties not presently known to the Company or that the Company presently believes are not material could also cause actual results or events to differ materially from those expressed in its forward-looking statements. Additional risks and uncertainties are discussed in the Company’s materials filed with the Canadian securities regulatory authorities from time to time, including, without limitation, the section entitled “Risks” in the Company’s AIF (for the year ended January 1, 2022). Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect the Company’s expectations only as of the date of this presentation. Except as required by law, the Company does not undertake to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

This presentation uses certain non-GAAP measures, such as Adjusted EBITDA, Adjusted EBITDA Margin, Retail Segment Adjusted Gross Profit, Retail Segment Adjusted Gross Profit Percentage, Adjusted Diluted Net Earnings Per Common Share and Free Cash Flow which the Company believes provide useful information to both management and investors in measuring the financial performance of the Company. These measures do not have a standardized meaning prescribed by GAAP, and therefore, they may not be comparable to similarly titled measures presented by other publicly traded companies and should not be construed as an alternative to other financial measures determined in accordance with GAAP.

# KEY FINANCIAL METRICS – Consolidated

## Q1 2022

(In CAD millions unless otherwise noted)

	Q1 2022	Q1 2021	% Change <sup>(1)</sup>
Consolidated Revenue	\$12,262	\$11,872	↑ +3.3%
Adjusted EBITDA	\$1,343	\$1,218	↑ +10.3%
Adjusted EBITDA Margin	11.0%	10.3%	↑ +70 bps
Adjusted Net Earnings Available to Common Shareholders	\$459	\$392	↑ +17.1%
Adjusted Diluted Net Earnings Per Common Share	\$1.36	\$1.13	↑ +20.4%
Free Cash Flow <sup>(2)</sup>	\$313	\$288	
Capex	\$186	\$203	

(1) ↑ indicates better; ↓ indicates worse; ≈ indicates flat

(2) The definition of free cash flow was changed since the first quarter of 2019 to normalize for the impact of the implementation of IFRS 16

# KEY FINANCIAL METRICS – Retail Segment

Q1 2022

(In CAD millions unless otherwise noted)

	Q1 2022	Q1 2021	% Change <sup>(1)</sup>	
Total Retail Revenue	\$12,045	\$11,670	↑	3.2%
Retail Revenue - Food	\$8,682	\$8,479	↑	2.4%
Retail Revenue - Drug	\$3,363	\$3,191	↑	5.4%
Pharmacy	\$1,724	\$1,614	↑	6.8%
Front Store	\$1,639	\$1,577	↑	3.9%
Adjusted Retail Gross Margin	31.1%	30.3%	↑	+80 bps
Adjusted Retail SG&A rate	20.4%	20.5%	↑	+10 bps
Adjusted Retail EBITDA	\$1,285	\$1,145	↑	12.2%
Adjusted Retail EBITDA Margin	10.7%	9.8%	↑	+90 bps

(1) ↑ indicates better; ↓ indicates worse; ≈ indicates flat

# KEY OPERATIONAL METRICS

## Q1 2022

### Food Retail (Loblaw)

	% Change <sup>(1)</sup>
Food Retail Same-Store Sales Growth	↑ 2.1%
Basket Size <sup>(2)</sup>	↓
Traffic <sup>(2)</sup>	↑
Loblaw STM Square Footage Growth	↓
Industry STM Square Footage Growth	↑

### Drug Retail (Shoppers Drug Mart)

	% Change <sup>(1)</sup>
Drug Retail Same-Store Sales Growth	↑ +5.2%
Pharmacy <sup>(2)</sup>	↑ +6.8%
Rx Count <sup>(3)</sup>	↑ +5.8%
Average Rx Value <sup>(3)</sup>	↑ +0.4%
Front Store <sup>(2)</sup>	↑ +3.6%

(1) ↑ indicates better; ↓ indicates worse; ≈ indicates flat

(2) Based on same-store sales

(3) Based on absolute sales